Deep Diving Into the Next Wave of Bioconjugate Design & Mechanisms to Overcome Payload Resistance & Enhance ADC Therapeutic Properties - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Deep Diving Into the Next Wave of Bioconjugate Design & Mechanisms to Overcome Payload Resistance & Enhance ADC Therapeutic Properties

9:30 am - Monday 12th October 2026

Breaking down the exciting landscape of novel drug conjugate design and mechanisms of action
Exploring emerging trends across conjugate design and targets
Spotlighting novel conjugate innovation across multi payload ADCs, bispecific ADCs and degrader antibody conjugates

Speakers:

Yu-Shin Hsu

Yu-Shin Hsu

Senior Research Analyst

Beacon